Organisation paid for research Program year 2025 Source: CMS Open Payments

Aa MRC LLC

Neither a doctor nor a teaching hospital

Research payments

$4,300,137

1,346 payments

Through program year 2025, Aa MRC LLC is reported as receiving $4,300,137 in research payments, across 1,346 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,037,431	68
2024	Research	$560,156	49
2023	Research	$492,848	281
2022	Research	$481,584	136
2021	Research	$517,866	316
2020	Research	$539,226	324
2019	Research	$671,026	172

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $797,632 37 payments
AstraZeneca Pharmaceuticals LP $647,274 37 payments
AbbVie, Inc. $526,560 119 payments
Novo Nordisk AS $471,108 817 payments
Genentech, Inc. $299,336 20 payments
Eli Lilly and Company $240,153 13 payments
Bayer HealthCare Pharmaceuticals Inc. $186,866 75 payments
GlaxoSmithKline, LLC. $141,881 40 payments
Pfizer Inc. $122,469 30 payments
Alnylam Pharmaceuticals Inc. $112,538 8 payments

Studies the money was for Research payments · program years 2019–2025

PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $184,051 11 payments
Ex9536-4388 $177,262 194 payments
Nn9924-4635 $158,239 126 payments
An Open-Label, Multi-Center Protocol for Patients Who Have Completed A Previous Novartis Sponsored Secukinumab Study and Are Judged By the Investigator to Benefit From Continued Secukinumab Treatment $139,766 4 payments
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $129,043 1 payment
A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $124,690 4 payments
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $121,009 26 payments
A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk $119,576 5 payments
Ph III OLE of Astegolimab in COPD $115,285 9 payments
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $112,538 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.